Scientific reports

phytomedicine : international journal of phytotherapy and phytopharmacology

Life sciences

Gene

Advances in therapy

lung cancer (amsterdam, netherlands)

Journal of pain and symptom management

Clinical drug investigation

chest

Thoracic cancer

Targeted oncology

Oncology and therapy

Skin health and disease

Public health in practice (Oxford, England)

[1] Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.

[2] The triazole linked galactose substituted dicyano compound can induce autophagy in NSCLC cell lines.

[3] Comparative Effectiveness of Robotic-Assisted Surgery for Resectable Lung Cancer in Older Patients.

[4] Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 27 RCTs.

[5] LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.

[6] Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer.

[7] Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.

[8] up-regulation of fstl3, regulated by lncrna dscam-as1/mir-122-5p axis, promotes proliferation and migration of non-small cell lung cancer cells

[9] editorial: update on the treatment of metastatic non-small cell lung cancer (nsclc) in new era of personalised medicine

[10] preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to n-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer

[11] the efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials

[12] in cancer cell lines inhibition of scf/c-kit pathway leads to radiosensitization only when scf is strongly over-expressed

[13] circulating plasma micrornas as diagnostic markers for nsclc

[14] long noncoding rna ak126698 inhibits proliferation and migration of non-small cell lung cancer cells by targeting frizzled-8 and suppressing wnt/β-catenin signaling pathway

[15] quality of life in patients with nsclc receiving maintenance therapy

[16] Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion.

[17] The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review.

[18] The impact of different distractions on outdoor visual search and object memory.

[19] Acthar Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence.

[20] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.

[21] Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.

[22] EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)-A Podcast Discussion Between Patients and Oncologists.

[23] Does equipoise exist for masking children for COVID-19?

[24] Mechanistic Insights and Therapeutic Potentials of Ubiquitin-Proteasome System in Non-Small Cell Lung Cancer.

[25] Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.

[26] Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC.

[27] Immunotherapy-based combinations in metastatic NSCLC

[28] Automated AJCC (7th edition) staging of non-small cell lung cancer (NSCLC) using deep convolutional neural network (CNN) and recurrent neural network (RNN).

[29] New modalities of cancer treatment for NSCLC: focus on immunotherapy

[30] New modalities of cancer treatment for NSCLC: focus on immunotherapy

[31] New modalities of cancer treatment for NSCLC: focus on immunotherapy

[32] The triazole linked galactose substituted dicyano compound can induce autophagy in NSCLC cell lines.

[33] Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis.

[34] New vision, new hope: Building momentum in NSCLC

[35] Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.

[36] Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

[37] Dodonaea viscosa Leaf Extract Assisted Synthesis of Gold Nanoparticles: Characterization and Cytotoxicity Against A549 NSCLC Cancer Cells

[38] Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC.

[39] mechanism of trim24 to regulate resistance of gefitinib in nsclc cells

[40] over-expression of chromatin assembly factor 1 subunit a (chaf1a) facilitates cell proliferation in non-small cell lung cancer (nsclc)

[41] editorial: update on the treatment of metastatic non-small cell lung cancer (nsclc) in new era of personalised medicine

[42] expression of carbonic anhydrase ix in nsclc and its relationship with vegf and ki67 expression

[43] expressions of c-cbl, cbl-b and egfr and its role of prognosis in nsclc

[44] circulating plasma micrornas as diagnostic markers for nsclc

[45] the novel small molecule stk899704 promotes senescence of the human a549 nsclc cells by inducing dna damage responses and cell cycle arrest

[46] review article: heat shock protein 70 (hsp70) peptide activated natural killer (nk) cells for the treatment of patients with non-small cell lung cancer (nsclc) after radiochemotherapy (rctx) – from preclinical studies to a clinical phase ii trial

[47] comparison of the superarms and droplet digital pcr for detecting egfr mutation in ctdna from nsclc patients

[48] quality of life in patients with nsclc receiving maintenance therapy

[49] ercc1 and class Ⅲ β-tubulin protein expression in relation to tumour response and survival of stage Ⅲb/Ⅳ nsclc patients treated with tp/np chemotherapy regimens

[50] internal dose escalation is associated with increased local control for non-small cell lung cancer (nsclc) brain metastases treated with stereotactic radiosurgery (srs)

[51] Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the Gene Have Durable Responses to ALK Kinase Inhibitors.

[52] Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis

[53] Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.

[54] EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)-A Podcast Discussion Between Patients and Oncologists.

[55] SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review.

[56] Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.

[57] Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival.

[58] Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC.

[59] Immunotherapy-based combinations in metastatic NSCLC